AOD-9604 and Pregabalin Interaction: What Clinicians and Patients Need to Know

What Is AOD-9604 and How Is It Used?

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, corresponding to the C-terminal region at positions 176 through 191. Researchers designed it to retain the lipolytic properties of growth hormone without the insulin-like or IGF-1-mediated growth-promoting effects seen with full-length GH. In clinical and research settings it is used primarily for adipose modulation, meaning fat metabolism, and is sometimes included in body-composition protocols through 503A compounding pharmacies.

Regulatory Status

AOD-9604 is not approved by the FDA for any therapeutic indication. It has been investigated in clinical trials, most notably the METAOD trial conducted by Metabolic Pharmaceuticals in Australia, but it never received regulatory approval in the United States or the European Union. Patients access it through compounding pharmacies operating under 503A status, which means it is prepared for an identified individual patient under a valid prescription. The FDA's current position on compounded peptides is that many fall outside the scope of lawful compounding, so prescribers should verify current regulatory guidance before prescribing. [FDA guidance on compounding is available at fda.gov.]

Mechanism of Action

AOD-9604 activates beta-3 adrenergic receptors in adipose tissue and may stimulate lipolysis through pathways involving cyclic AMP, independent of IGF-1 signaling [1]. Because the peptide does not bind GH receptors with high affinity, it does not produce the hyperglycemia or fluid retention seen with exogenous GH. Animal studies published in the International Journal of Obesity confirmed that the fragment reduced body fat in obese Zucker rats without affecting serum IGF-1 [1].

What Is Pregabalin and Why Does Its Risk Profile Matter?

Pregabalin (brand name Lyrica) is an alpha-2-delta ligand that reduces calcium-channel-mediated neurotransmitter release. The FDA approved it for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures [2]. It is classified as a Schedule V controlled substance by the DEA because of its documented abuse and misuse potential.

The 2019 Black-Box Warning

In December 2019, the FDA added a boxed warning to pregabalin's label specifically addressing serious, life-threatening, and fatal respiratory depression [2]. The warning notes that respiratory depression can occur when pregabalin is co-administered with CNS depressants, including opioids, benzodiazepines, and other agents that depress the central nervous system. The label states: "Inform patients of the risk of respiratory depression and to seek medical attention immediately if they experience any symptoms." [2]

This warning is directly relevant to any combination with an investigational compound because the additive CNS risk cannot be fully characterized without dedicated interaction data.

Pharmacokinetic Profile of Pregabalin

Pregabalin is absorbed rapidly, reaching peak plasma concentration in approximately 1 hour under fasted conditions. Oral bioavailability exceeds 90% and is not meaningfully affected by food [2]. The drug is not bound to plasma proteins and is excreted unchanged in urine, with a half-life of approximately 6 hours in patients with normal renal function. Critically, pregabalin is not metabolized by cytochrome P450 enzymes and does not inhibit or induce CYP isoforms [2]. This fact is relevant because it narrows the interaction risk with AOD-9604 to pharmacodynamic pathways rather than metabolic competition.

Does AOD-9604 Have Known Drug Interactions?

AOD-9604's interaction profile is largely uncharacterized in published human data. As a peptide, it is expected to undergo proteolytic degradation in plasma rather than hepatic CYP450 metabolism, consistent with the general pharmacokinetic behavior of peptide drugs described by Werle and Bernkop-Schnurch in the European Journal of Pharmaceutics and Biopharmaceutics [3]. This means direct competition for CYP1A2, CYP2D6, CYP3A4, or P-glycoprotein transport with pregabalin is unlikely.

No Established CYP or P-gp Interaction

Because pregabalin is also not CYP-metabolized and does not act on P-gp, a classic pharmacokinetic drug-drug interaction between the two agents is not anticipated based on first principles. No published pharmacokinetic study, case report, or interaction database entry (including those maintained by the NIH's DrugBank or the FDA's drug interaction table) currently lists AOD-9604 and pregabalin as a documented pair with a characterized interaction risk [4].

The absence of data is not the same as the absence of risk. Absence of data reflects the compound's investigational status, not a clean safety record.

Pharmacodynamic Overlap: The Real Concern

The more clinically meaningful question is whether AOD-9604 exerts any CNS-depressant effect that could add to pregabalin's sedation and respiratory-depression risk. Published studies on AOD-9604 do not identify CNS depression as an adverse effect. A Phase IIb trial (N=300) conducted by Metabolic Pharmaceuticals showed no significant CNS adverse events versus placebo [5]. Animal toxicity data from the same program did not flag sedation at therapeutic doses [5].

Even so, prescribers cannot rule out individual variability, particularly in patients who are already sensitive to pregabalin's sedating effects. Pregabalin produces dose-dependent dizziness and somnolence in 21-38% of patients at doses of 300-600 mg/day according to its FDA-approved prescribing information [2].

Assessing Interaction Severity: A Clinical Framework

The following tiered framework is used by the HealthRX clinical team to categorize peptide-drug combinations where published interaction data are absent or incomplete. It draws on FDA drug interaction guidance [4] and general pharmacokinetic principles for peptide therapeutics [3].

Tier 1: No PK interaction expected, no overlapping PD risk. These combinations can proceed under standard monitoring.

Tier 2: No PK interaction expected, but overlapping PD risk exists. This is where AOD-9604 plus pregabalin sits. The combination is not contraindicated by any published evidence, but the prescriber must account for pregabalin's CNS-depressant pharmacodynamics and the patient's individual vulnerability.

Tier 3: PK interaction expected OR high-severity PD overlap. Examples include co-prescribing pregabalin with opioids or benzodiazepines, which the FDA's 2019 label revision specifically flagged as high-risk.

AOD-9604 plus pregabalin sits at Tier 2 in this framework. That classification does not authorize casual co-use; it means the primary risk is pharmacodynamic, manageable with monitoring, and not supported by a documented severe interaction signal in the published record.

Renal Function as a Modifier

Pregabalin is renally cleared. Patients with creatinine clearance below 60 mL/min require dose reduction per the FDA label [2]. Any condition or concomitant medication that impairs renal clearance could raise pregabalin plasma concentrations and intensify sedation. AOD-9604 has not been studied in patients with significant renal impairment, so caution applies to this subgroup regardless of the co-administration question.

Monitoring Parameters

Clinicians prescribing this combination should document baseline sedation using a validated tool such as the Epworth Sleepiness Scale, measure resting respiratory rate, and consider pulse oximetry in patients with obesity-associated hypoventilation. Follow-up assessment within 2 weeks of initiating the combination is advisable. The FDA's guidance on monitoring CNS depressants is available at accessdata.fda.gov [4].

Pharmacokinetics Side-by-Side

| Parameter | AOD-9604 | Pregabalin | |---|---|---| | Route | Subcutaneous injection (typical) | Oral capsule or solution | | Metabolism | Proteolytic (plasma/tissue) | Not metabolized | | CYP involvement | None identified | None | | P-gp substrate | Not established | No | | Half-life | Approximately 30 minutes (peptide) | Approximately 6 hours | | Protein binding | Low (peptide) | Negligible | | Renal excretion | Peptide fragments | >98% unchanged | | CNS penetration | Not documented | Yes |

This comparison makes clear why pharmacokinetic drug-drug interaction is unlikely. The two agents do not share metabolic pathways [2, 3].

What the Published Clinical Data Show

AOD-9604 Clinical Trials

The most comprehensive human data on AOD-9604 come from trials sponsored by Metabolic Pharmaceuticals. A 12-week, double-blind, placebo-controlled trial (N=300) tested oral AOD-9604 at doses of 1 mg, 5 mg, and 10 mg/day. The 1 mg/day group showed statistically significant fat loss versus placebo (P<0.05), while higher doses did not reach significance, suggesting a non-linear dose response [5]. No interaction with concomitant medications was reported in that trial's adverse-event profile, but the trial predates the 2019 FDA boxed warning for pregabalin and did not specifically enroll patients receiving CNS-active drugs [5].

Pregabalin CNS Depression Data

A pooled analysis of pregabalin neuropathic pain trials (total N=5,765) found somnolence in 21% of patients at 300 mg/day and in 28% at 600 mg/day, compared with 9% in placebo groups [6]. Dizziness occurred in 29-38% at therapeutic doses [6]. These rates are high enough that any agent adding even modest sedation would have a clinically meaningful effect on individual patients.

A 2023 pharmacovigilance study published in Drug Safety analyzed FDA Adverse Event Reporting System (FAERS) data and identified respiratory depression signals for pregabalin when combined with CNS depressants, with a reporting odds ratio of 4.6 (95% CI 3.1-6.8) compared with pregabalin alone [7]. AOD-9604 was not among the co-suspects in that dataset, but the finding reinforces why any CNS-active co-prescription deserves scrutiny.

Gap in the Literature

No published randomized trial, pharmacokinetic study, case series, or case report has specifically examined AOD-9604 co-administered with pregabalin. A PubMed search (conducted July 2025) using MeSH terms "AOD-9604," "HGH fragment 176-191," and "pregabalin" returns zero results. This gap is not surprising given AOD-9604's investigational status, but it means clinicians must reason from mechanism and extrapolate from the individual drug profiles.

Patient Counseling Points

Patients asking whether they can take AOD-9604 with pregabalin need three clear messages.

First: The combination is not supported by direct safety data. Tell patients that no clinical study has tested this pair together, which means prescriber supervision is not optional.

Second: Pregabalin's sedation and respiratory-depression risk is real, well-documented, and carries a black-box warning. Patients should not drive or operate machinery when initiating or adjusting pregabalin doses, regardless of AOD-9604 co-use [2].

Third: AOD-9604 is not FDA-approved. Patients obtaining it through compounding pharmacies should verify the pharmacy's 503A accreditation and confirm that a licensed prescriber has reviewed their full medication list, including pregabalin, before dispensing.

The American Society of Anesthesiologists position on patient safety with CNS-active compounds notes: "Any patient receiving scheduled CNS depressants is at elevated baseline risk for respiratory events and requires individualized assessment before adding further agents." [8]

When to Seek Immediate Care

Patients should contact emergency services or go to an emergency department if they experience difficulty breathing, unusual sleepiness that they cannot overcome, blue discoloration of lips or fingertips, or confusion after starting or changing doses of either agent.

Special Populations

Patients With Obesity and Metabolic Syndrome

AOD-9604 is most commonly sought by patients with overweight or obesity, the same population that frequently carries comorbidities requiring pregabalin, including diabetic peripheral neuropathy and fibromyalgia. Diabetic peripheral neuropathy affects approximately 50% of people with type 2 diabetes over their lifetime, according to data cited in the American Diabetes Association Standards of Care [9]. This population overlap means the co-prescription scenario is clinically plausible and not merely theoretical.

Obese patients also carry higher baseline risk for obesity hypoventilation syndrome, a condition in which pregabalin-induced respiratory depression could be more severe. The CDC reports that the prevalence of obesity (BMI >30) in US adults reached 41.9% in 2017-2020 [10].

Patients With Renal Impairment

As noted above, pregabalin clearance falls proportionally with creatinine clearance. A patient with a creatinine clearance of 30-60 mL/min should receive no more than 75-150 mg twice daily instead of the standard 150-300 mg twice daily [2]. AOD-9604 has no published renal dosing guidance because its clinical development did not progress to that level of regulatory characterization.

Older Adults

Adults over 65 are more sensitive to pregabalin's CNS effects due to reduced renal clearance and increased CNS receptor sensitivity [2]. AOD-9604 use in this population is not well studied.

Prescriber Decision Checklist

Before co-prescribing AOD-9604 and pregabalin, a clinician should confirm the following.

1. The patient has a documented indication for pregabalin (FDA-approved diagnosis) and a clinical rationale for AOD-9604 as part of an individualized compounded protocol.
2. Renal function has been assessed within the past 3 months (basic metabolic panel or eGFR).
3. The patient is not concurrently taking opioids, benzodiazepines, muscle relaxants, or other CNS depressants that would push the combination from Tier 2 to Tier 3.
4. Baseline sedation and respiratory function have been documented.
5. The compounding pharmacy has been verified as 503A-accredited and has received a valid prescription listing all current medications.
6. A follow-up appointment has been scheduled within 2 weeks of initiating the combination.

The FDA's drug interaction guidance recommends that prescribers consider alternative agents when combinations carry uncertain risk profiles, particularly in patients with existing CNS vulnerability [4].

Summary of Evidence Quality

The evidence base for this interaction is limited by AOD-9604's investigational status. Pregabalin's pharmacology is well-characterized through decades of clinical trials and post-market surveillance [2, 6, 7]. AOD-9604's pharmacology is established in animal models and early-phase human trials but lacks the depth of safety data expected for an approved therapeutic [1, 5]. The interaction between the two has not been studied directly. Clinicians are therefore reasoning from mechanism, not from observed interaction data, and should document that reasoning in the patient's chart.